Background: Well-designed epidemiologic investigations of pediatric cancer survivors inform clinical practice guidelines and future clinical trials. Expansion of the CCSS cohort to include survivors diagnosed across three decades affords the opportunity to evaluate associations between key temporal changes in survivor treatment characteristics and risk for adverse health outcomes.
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Methods:
We summarized changes in cancer and treatment characteristics of 24,000 CCSS participants. Treatment exposures were abstracted from medical records. Trends across 5 year intervals were evaluated using logistic regression models with weights to account for sampling probabilities.
Results:
Within the expanded CCSS, use of chemotherapy significantly increased overall (Table, T1-T6) and for each diagnosis except leukemia which was always 100%. Exposure to radiation (RT) decreased overall and for each diagnosis except soft tissue sarcoma. Overall, chest RT exposure was reduced and notably, exposures of ≥ 30 Gy declined from 85% to 6% (T1 to T6) for Hodgkin lymphoma. Use of anthracyclines (ANT) increased significantly, predominantly for doses lower than 250 mg/m 
